Serum EVs from patients with stage I/II gastric cancer contain elevated levels of one lncRNA (GClnc1), suggesting its potential as a biomarker for distinguishing patients with early gastric cancer from healthy individuals and those with precancerous conditions such as chronic atrophic gastritis and intestinal metaplasia [63]. This evidence concerns the gene SOD2 and gastric cancer.